CASE REPORT FORM APPROVAL SIGNATURE PAGE

Study Titile:

Guidelines Oriented Approach to Lipid lowering Quality

Enhancement Research Initiative (GOAL QuERI) International

The signature below consitutes the apporval of the case report form version dated February 20, 2019 reflecting data to be collected in accordance with the GOAL INTERNATIONAL study protocol version dated January 28, 2019.

Anatoly Langer, MD, MSc, FRCPC, FACC Chair, Canadian Heart Research Centre

Date (Day/Month/Year)

PATIENT ELIGIBILITY

Visit 1 page 1

eCRF Portal - Add New Patient

Patient Number: XXXX Patient's Initials: Inclusion Criteria: ALL of the criteria must be present 1. Please confirm □ Adults ≥ 18 years old 2. Please confirm □ High risk for cardiovascular morbidity and mortality defined as clinical atherosclerotic cardiovascular disease (CVD) and/or familial hypercholesterolemia 3. Please confirm □ Receiving current optimal (maximal or maximal tolerated) statin therapy for at least 3 months prior to enrolment 4. Please confirm \Box LDL-C above currently recommended target by the Canadian Cardiovascular Society measured while on maximal tolerated statin therapy (± other lipid modifying therapies). 5. Please confirm □ Desire and ability to execute the consent to participate **Exclusion Criteria: None of the criteria present** 1. Current treatment with PCSK9 inhibitor 2. Current participation in investigational study 3. Prior participation in GOAL program This patient does **NOT** have any of the above Exclusion Criteria

Date: Feb 20, 2019

Visit Date: (yyyy/mm/dd)

Visit 1 page 2

eCRF Portal - Add New Patient

DEMOGRAPHICS AND HISTORY Patient Number: XXXX

Gender:
© Male
© Female
Age: (years)
Ethnicity: Select one from the drop down menu
Please Select 👻
Drop down list: Aboriginal Canadian (First Nations / Metis / Inuit), Arabic / North African, Black, Caucasian / White, Hispanic, East / South-East Asian, Multi-Racial, South Asian, Other
Smoking History: Select one from the drop down menu
Please Select Drop down list: Never Smoked, Past Smoker, Current Smoker
Medication Insurance Coverage:
Please Select Drop down list: Private, Public
If Private:
[©] Employer
[©] Self pa <u>y</u>
Other

CO-MORBIDITIES Select Yes/No for each of the following	Ye	s No
Coronary Artery Disease	0	•
Cerebrovascular Disease	୍	•
Abdominal Aortic Aneurism	୍	©
Peripheral Arterial Disease	c	0
Diabetes Mellitus	C	C
Treated Hypertension	c	0
Chronic Kidney Disease	୍	©
Microvascular Disease (retinopathy, neuropathy)	င	0
Familial Hypercholesterolemia	േ	C
Premature Family History or CV disease (1º relative – 55 yo/male, 65 yo/female)	୍	©
Atrial Fibrillation	0	୍
Congestive Heart Failure	୍	•
Cancer	୍	0
Liver Disease	0	C

(Note: The following sub-comorbidities will be displayed if Yes to Coronary artery disease, Cerebrovascular disease, Diabetes mellitus, microvascular disease, and familial hypercholesterolemia.)

History of Coronary Artery Disease (CAD)	
Check ALL that Apply (at least ONE must be checked)	
Myocardial Infarction or Acute Coronary Syndrome	
Coronary artery bypass surgery	
Percutaneous coronary intervention	
Angiographic disease (>50% stenosis with stable angina)	
History of Cerebrovascular Disease (CeVD) Check ALL that Apply (at least ONE must be checked)	
Cerebrovascular Accident	
Transient ischemic attack	
Carotid Surgery	
2DM Duration Select one from the drop down menu Please Select	
Microvascular Disease Check ALL that Apply (at least ONE must be checked)	
Microalbuminuria	
eGFR < 60 mL/min	
Neuropathy	
Retinopathy	

Familial Hypercholesterolemia LDL-C > 5mmol/L prior to lipid lowering therapy and one of:	
Check ALL that Apply (at least ONE must be checked)	
Typical physical findings (stigmata) such as tendon xanthomata, xanthelasma, and corneal arcus	
Personal history of premature cardiovascular disease	
Family history of premature cardiovascular disease or of marked hyperlipidemia	

Date: Feb 20, 2019 Page **6** of **22**

Visit 1 page 3

eCRF Portal - Add New Patient

MEDICATION AND PHYSICAL ASSESSMENT Patient Number: XXXX

CURRENT MEDICATION (OTHER THAN LIPID MODIFYING THERAPY) Select Yes/No for each of the following		s No
ASA	0	0
Other Antiplatelet Agent (Clopidogrel, Prasugrel, Ticagrelor)	• 6	୍
ACE-Inhibitor	0	0
Angiotensin Receptor Blocker (ARB)	0	C
Beta-Blocker	0	C
Calcium Channel Blocker	0	୍
Diuretic	0	0
Warfarin	0	0
Direct Oral Anticoagulation Agent	ତ	C
Valsartan/Succubitril	0	C
Spironolactone/Eplerenon	0	୍

Date: Feb 20, 2019 Page **7** of **22**

(Note: If Diabetic Mellitus=Yes on page 2, then display Antihyperglycemic medications)

ANTIHYPERGLYCEMIC MEDICATION Select Yes/No for each of the following	Yes	No
a-Glucosidase Inhibitor	0	0
DPP-4 Inhibitor	C	©
GLP-1 Receptor Agonist	•	C
Insulin	©	©
Meglitinide	©	0
Metformin	େ	0
Metformin/DPP-4 Fixed Dose Combination	0	©
SGLT2 Inhibitor	0	©
Sulfonylurea	0	•
Thiazolidinedione	o	୍

CURRENT LDL LOWERING THERAPY: Select Yes/No for each of the following	Yes	No
Statin		
Statin	©	0
Bile Acid Sequestrant	C	C
Ezetimibe	C	C
Fibrate	୍	0
Niacin	©	C
Please confirm that this patient is on maximal tolerated statin dose which include no statin therapy in case of complete intolerance Yes No	າ may	
PHYSICAL ASSESSMENT		
Blood Pressure		
Systolic mmHg		
Diastolic mmHg		
Heart Rate bpm		
Weight kg C lbs		
Height C cm o in		
liac Waist Circumference f the Iliac Waist Circumference is Not Available, check the N/A box		
Cm Cin CN/A		

Visit 1 page 4

eCRF Portal - Add New Patient

LIPID PROFILE AND MANAGEMENT Patient Number: XXXX

Record values exactly as they appear in the lab report. Include decimal places where applicable

Most Recent Lab Date: (yyyy/mm/dd)

Total Cholesterol:

mmol/L

LDL-C:

mmol/L

HDL-C:

mmol/L

Non HDL-C:

mmol/L

Apo-B:

If Apo-B is Not Available, check the N/A box

● g/L ○ mg/dL ○ N/A

Date: Feb 20, 2019

Triglycerides:

Current Statin Therapy:

200	*****		
-	Please Select	¥	¥
3		222222	 2000

Drop down list: Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin, No statin

Statin dosage will display depend on the chosen statin

n light of the LDL-C and/or non-HDL-C level will you add one or more of the ollowing lipid lowering therapies? elect Yes/No for each of the following		sNo
PCSK9i (evolocumab)	0	0
PCSK9i (alirocumab)	C	େ
Bile Acid Sequestrant	C	୍
Fibrate	୍	0
Ezetimibe	େ	c
Niacin	0	c

Date: Feb 20, 2019 Page **11** of **22**

(Note: If Ezetimibe = No, display reasons why not (only one reason is allowed))

prescription to this patient at this visit: Select only one	
Patient Refusal	O
Patient intolerant	୍
Not Needed	0
Co-morbidities	0
Cost	© '
Patient is on PCSK9i	•
Patient will return for Rx/Will provide Rx at next patient visit.	•
Please note that ezetimibe is recommended to achieve lower LDL.	

(Note: If PCK9i = No, display reasons why not (only one reason is allowed))

Please select the most applicable reason for not providing the PCSK9i p	roccrintian
to this patient at this visit:	rescription
Select only one	
Patient Refusal	0
Patient intolerant	
adent intolerant	0
Not Needed	_
	6
Co-morbidities Co-morbidities	©
Cost	
	O
Patient will return for Rx/Will provide Rx at next patient visit.	6
Please note that PCSK9i is recommended to achieve lower LDL.	
The state of the s	

Visit 1 signoff page

eCRF Portal - Add New Patient

This e-CRF is COMPLETE Patient Number: XXXX

You have successfully completed the e-CRF for this patient. You can either <u>Submit</u> or <u>Review / Modify</u> the e-CRF

Please note that Visit 2 for this subject may be completed

If you click the "SUBMIT e-CRF" button, the data entered for this patient will be considered final and no modifications to any of the data fields can be made.

If you click the "REVIEW e-CRF" button, you will be able to review all previous pages of this e-CRF and make any applicable modifications if warranted. Once you have reviewed / modified the e-CRF to your satisfaction, you will be able to submit the final.

Visit 2 page 1

eCRF Portal

Patient Number: XXXX

Is the Patient Lost to Follow-up?
° Yes ° No
If YES, please select
Please Select

Drop down list if Yes is selected:

Patient died

Patient is lost to follow-up (moved, no longer being followed-up by physician)

Patient withdrew consent

Physician took patient out

Since Last Visit has the Patient Experienced the Following Select Yes/No for each of the following		Yes No		
Acute Coronary Syndrome	•	0		
Cerebro-Vascular Accident/Transient Ischemic Attack	•	0		
Coronary Artery Bypass Grafting	©	0		
Percutaneous Coronary Intervention	୍ର	©		
Hospitalization for cardiovascular diagnosis	•	6		
Visit Date: (yyyy/mm/dd)	***	****		

Visit 2 page 2

eCRF Portal

MEDICATION AND PHYSICAL ASSESSMENT Patient Number: xxxx

PHYSICAL ASSESSMENT	
Blood Pressure	
Systolic mmHg	
Diastolic mmHg	
Heart Rate	
bpm	
Weight	
© kg ● lbs	
Height	
C cm € in	
liac Waist Circumference	
f the Iliac Waist Circumference is Not Availabl	le, check the N/A box
ີ cm	

CURRENT LDL LOWERING THERAPY: Select Yes/No for each of the following	Yes	No
Statin	•	0
PCSK9i	•	0
Bile Acid Sequestrant	•	© ,
Ezetimibe	•	೦
Fibrate	•	0
Niacin	•	0

Visit 2 page 3

eCRF Portal

LIPID PROFILE AND MANAGEMENT Patient Number: XXXX

Record values exactly as they appear in the lab report. Include decimal places where applicable

Most Recent Lab Date: (yyyy/mm/dd)

Total Cholesterol:

Total Ch	nolesterol:	·
	mmol/L	
LDL-C:	mmol/L	
HDL-C:	•	
	mmol/L	
Non HDL	L-C:	
	mmol/L	
Triglycer	ides:	
	mmol/L	
Аро-В:		

If Apo-B is Not Available, check the N/A box

Date: Feb 20, 2019

● g/L [©] mg/dL [©] N/A

Current Statin Therapy:

The same of the sa	***************************************	
Please Select	¥	
J.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		*

Drop down list: Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin, No statin

Statin dosage will display depend on the chosen statin

In light of the LDL-C and/or non-HDL-C level will you add one or more of the following lipid lowering therapies? Select Yes/No for each of the following		YesNo	
PCSK9i (evolocumab)		0	C
PCSK9i (alirocumab)	W -	୍	୍
Bile Acid Sequestrant		୍	0
Fibrate		୍	O .
Ezetimibe		േ	
Niacin		0	୍

(Note: If Ezetimibe = No, display reasons why not (only one reason is allowed))

Please select the most applicable reason for not providing the Ezetimibe prescription to this patient at this visit: Select only one	
Patient Refusal	•
Patient intolerant	©
Not Needed	୍
Co-morbidities	•
Cost	ତ
Patient is on PCSK9i	0
Patient will return for Rx/Will provide Rx at next patient visit.	©
Please note that ezetimibe is recommended to achieve lower LDL.	
and the second of the second o	

(Note: If PCK9i = No, display reasons why not (only one reason is allowed))

Please select the most applicable reason for not providing the PCSK9i pr to this patient at this visit: Select only one	escription
Patient Refusal	0
Patient intolerant	0
Not Needed	
Co-morbidities	© ©
Cost	_
Patient will return for Rx/Will provide Rx at next patient visit.	© ©
Please note that PCSK9i is recommended to achieve lower LDL.	

Visit 2 signoff page

This e-CRF is COMPLETE Patient Number: xxxx

You have successfully completed the e-CRF for this patient. You can either <u>Submit</u> or <u>Review / Modify</u> the e-CRF

Please note that Visit 3 for this subject may be completed

If you click the "SUBMIT e-CRF" button, the data entered for this patient will be considered final and no modifications to any of the data fields can be made.

If you click the "REVIEW e-CRF" button, you will be able to review all previous pages of this e-CRF and make any applicable modifications if warranted. Once you have reviewed / modified the e-CRF to your satisfaction, you will be able to submit the final.

(Note: Visits 3 and 4 have the same display as Visit 2)